|
Q4 2024
|
12 |
169,025 |
UTHR, EXEL, CAH, BIIB
|
13F-HR
|
2/18/2025 |
000160925125000001 |
|
Q4 2024
|
12 |
169,025 |
UTHR, EXEL, CAH, BIIB
|
RESTATEMENT
|
2/18/2025 |
000160925125000002 |
|
Q3 2024
|
13 |
178,461 |
UTHR, EXEL, CAH, BIIB
|
13F-HR
|
11/14/2024 |
000164227424000006 |
|
Q2 2024
|
13 |
217,801 |
EXEL, UTHR, BIIB, TARO
|
13F-HR
|
8/14/2024 |
000160925124000006 |
|
Q1 2024
|
12 |
225,525 |
EXEL, UTHR, BIIB, TARO
|
13F-HR
|
5/15/2024 |
000160925124000005 |
|
Q4 2023
|
12 |
281,853 |
EXEL, UTHR, BIIB, REGN
|
13F-HR
|
2/14/2024 |
000160925124000002 |
|
Q3 2023
|
12 |
271,606 |
UTHR, EXEL, BIIB, REGN
|
13F-HR
|
11/14/2023 |
000160925123000005 |
|
Q2 2023
|
12 |
315,622 |
BIIB, UTHR, REGN, EXEL
|
13F-HR
|
8/11/2023 |
000160925123000004 |
|
Q1 2023
|
12 |
329,274 |
BIIB, REGN, UTHR, EXEL
|
13F-HR
|
5/15/2023 |
000160925123000003 |
|
Q4 2022
|
12 |
323,644 |
UTHR, BIIB, REGN, ALKS
|
13F-HR
|
2/15/2023 |
000160925123000001 |
|
Q3 2022
|
14 |
314,064 |
BIIB, UTHR, REGN, ALKS
|
13F-HR
|
11/14/2022 |
000160925122000005 |
|
Q2 2022
|
14 |
302,495 |
UTHR, ALKS, REGN, EXEL
|
13F-HR
|
8/15/2022 |
000160925122000004 |
|
Q1 2022
|
13 |
290,135 |
REGN, ENTA, MCK, ALKS
|
13F-HR
|
5/16/2022 |
000160925122000003 |
|
Q4 2021
|
10 |
288,314 |
UTHR, REGN, ENTA, MCK
|
13F-HR
|
2/14/2022 |
000160925122000002 |
|
Q3 2021
|
13 |
318,782 |
ENTA, ALKS, REGN, UTHR
|
13F-HR
|
11/15/2021 |
000160925121000006 |
|
Q2 2021
|
13 |
294,544 |
REGN, ALKS, ENTA, UTHR
|
13F-HR
|
8/13/2021 |
000160925121000005 |
|
Q1 2021
|
12 |
288,899 |
ENTA, UTHR, TARO, REGN
|
13F-HR
|
5/17/2021 |
000160925121000004 |
|
Q4 2020
|
12 |
342,426 |
ALXN, UTHR, TARO, REGN
|
13F-HR
|
2/17/2021 |
000160925121000001 |
|
Q3 2020
|
11 |
314,096 |
REGN, ALXN, UTHR, BIIB
|
RESTATEMENT
|
12/8/2020 |
000160925120000008 |
|
Q2 2020
|
11 |
367,575 |
UTHR, ALXN, REGN, BIIB
|
RESTATEMENT
|
8/20/2020 |
000160925120000006 |
|
Q1 2020
|
13 |
310,898 |
UTHR, REGN, ALXN, ENTA
|
13F-HR
|
5/18/2020 |
000160925120000003 |
|
Q4 2019
|
12 |
293,048 |
UTHR, REGN, MCK, ALXN
|
13F-HR
|
2/18/2020 |
000160925120000001 |
|
Q3 2019
|
10 |
260,445 |
UTHR, BIIB, MCK, GILD
|
13F-HR
|
11/15/2019 |
000160925119000007 |
|
Q2 2019
|
10 |
308,111 |
MCK, UTHR, BIIB, ENTA
|
13F-HR
|
8/14/2019 |
000160925119000006 |
|
Q1 2019
|
12 |
370,055 |
UTHR, MCK, ENTA, BIIB
|
13F-HR
|
5/15/2019 |
000160925119000005 |
|
Q4 2018
|
13 |
296,165 |
UTHR, MCK, ENTA, AMGN
|
RESTATEMENT
|
2/15/2019 |
000160925119000003 |
|
Q3 2018
|
14 |
389,139 |
UTHR, MCK, AMGN, ENTA
|
13F-HR
|
11/14/2018 |
000160925118000007 |
|
Q2 2018
|
14 |
391,605 |
UTHR, ENTA, AMGN, MCK
|
13F-HR
|
8/13/2018 |
000160925118000006 |
|
Q1 2018
|
16 |
412,201 |
UTHR, ENTA, AMGN, MCK
|
13F-HR
|
5/14/2018 |
000160925118000005 |
|
Q4 2017
|
16 |
320,818 |
ENTA, UTHR, BIOVERATIV INC, GILD
|
13F-HR
|
2/14/2018 |
000160925118000002 |
|
Q3 2017
|
14 |
320,803 |
ENTA, GILD, UTHR, BIOVERATIV INC
|
13F-HR
|
11/14/2017 |
000160925117000008 |
|
Q2 2017
|
15 |
329,397 |
BIOVERATIV INC, ENTA, GILD, UTHR
|
13F-HR
|
8/14/2017 |
000160925117000007 |
|
Q1 2017
|
15 |
310,101 |
BIOVERATIV INC, GILD, ENTA, UTHR
|
13F-HR
|
5/15/2017 |
000160925117000006 |
|
Q4 2016
|
16 |
278,919 |
UTHR, ENTA, GILD, SUCAMPO PHARMACEUTICALS-CL A
|
13F-HR
|
2/13/2017 |
000160925117000001 |
|
Q3 2016
|
17 |
276,731 |
UTHR, OFIX, ENTA, IPXL
|
13F-HR
|
11/14/2016 |
000160925116000011 |
|
Q2 2016
|
20 |
277,542 |
UTHR, OFIX, IPXL, ENTA
|
13F-HR
|
8/12/2016 |
000160925116000010 |
|
Q1 2016
|
22 |
278,703 |
BXLT, OFIX, ENTA, UTHR
|
13F-HR
|
5/13/2016 |
000160925116000009 |
|
Q4 2015
|
22 |
313,414 |
UTHR, ENTA, BXLT, TEVA
|
13F-HR
|
2/12/2016 |
000160925116000007 |
|
Q3 2015
|
23 |
276,257 |
ENTA, UTHR, BXLT, TEVA
|
13F-HR
|
11/13/2015 |
000160925115000006 |
|
Q2 2015
|
22 |
265,146 |
ENTA, UTHR, IPXL, TEVA
|
13F-HR
|
8/13/2015 |
000160925115000004 |
|
Q1 2015
|
23 |
219,568 |
UTHR, IPXL, AMAG, TEVA
|
13F-HR
|
5/13/2015 |
000160925115000002 |
|
Q4 2014
|
26 |
179,479 |
UTHR, AMAG, SUCAMPO PHARMACEUTICALS-CL A, IPXL
|
13F-HR
|
2/18/2015 |
000160925115000001 |